Brokers Offer Predictions for Mirati Therapeutics Inc’s Q2 2019 Earnings (NASDAQ:MRTX)

Mirati Therapeutics Inc (NASDAQ:MRTX) – Equities research analysts at B. Riley issued their Q2 2019 earnings per share estimates for shares of Mirati Therapeutics in a report issued on Wednesday, June 19th, Zacks Investment Research reports. B. Riley analyst H. Polishetty forecasts that the biotechnology company will post earnings of ($1.23) per share for the quarter. B. Riley currently has a “Neutral” rating and a $92.00 price target on the stock. B. Riley also issued estimates for Mirati Therapeutics’ Q3 2019 earnings at ($1.29) EPS, Q4 2019 earnings at ($1.33) EPS, FY2019 earnings at ($5.02) EPS, FY2020 earnings at ($5.05) EPS, FY2021 earnings at ($5.89) EPS, FY2022 earnings at ($6.94) EPS and FY2023 earnings at ($5.54) EPS.

Mirati Therapeutics (NASDAQ:MRTX) last announced its quarterly earnings data on Monday, April 29th. The biotechnology company reported ($1.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.20). The firm had revenue of $1.24 million during the quarter.

A number of other equities research analysts have also recently issued reports on the company. Cantor Fitzgerald upped their price objective on Mirati Therapeutics from $66.00 to $85.00 and gave the stock a “positive” rating in a research note on Tuesday, June 4th. Guggenheim cut Mirati Therapeutics from a “buy” rating to a “neutral” rating and set a $95.56 price objective on the stock. in a research note on Friday, June 7th. Credit Suisse Group set a $155.00 price objective on Allergan and gave the stock a “hold” rating in a research note on Monday, March 25th. SunTrust Banks upped their price objective on Mirati Therapeutics to $120.00 and gave the stock a “buy” rating in a research note on Tuesday, June 4th. Finally, HC Wainwright reiterated a “buy” rating on shares of Zomedica Pharmaceuticals in a research note on Wednesday, June 5th. One analyst has rated the stock with a sell rating, four have issued a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. Mirati Therapeutics has a consensus rating of “Buy” and a consensus target price of $95.33.

Shares of Mirati Therapeutics stock traded up $0.21 on Friday, reaching $105.71. 265,561 shares of the company were exchanged, compared to its average volume of 582,893. Mirati Therapeutics has a one year low of $28.50 and a one year high of $109.64. The firm has a market cap of $3.80 billion, a P/E ratio of -33.14 and a beta of 2.02. The firm’s 50-day moving average is $95.84.

In related news, Director Michael G. Grey sold 5,760 shares of the stock in a transaction on Monday, May 13th. The stock was sold at an average price of $65.30, for a total value of $376,128.00. Following the sale, the director now owns 7,100 shares in the company, valued at approximately $463,630. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Bruce L. A. Carter sold 3,000 shares of the stock in a transaction on Wednesday, May 22nd. The shares were sold at an average price of $75.20, for a total value of $225,600.00. Following the completion of the sale, the director now owns 3,000 shares in the company, valued at approximately $225,600. The disclosure for this sale can be found here. In the last 90 days, insiders sold 16,260 shares of company stock worth $1,164,228. 4.86% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of MRTX. CWM LLC acquired a new position in Mirati Therapeutics in the 1st quarter valued at $40,000. Legal & General Group Plc grew its holdings in Mirati Therapeutics by 16.5% in the 4th quarter. Legal & General Group Plc now owns 3,635 shares of the biotechnology company’s stock valued at $154,000 after buying an additional 515 shares in the last quarter. Meeder Asset Management Inc. grew its holdings in Mirati Therapeutics by 7.9% in the 1st quarter. Meeder Asset Management Inc. now owns 2,252 shares of the biotechnology company’s stock valued at $166,000 after buying an additional 165 shares in the last quarter. Creative Planning acquired a new position in Mirati Therapeutics in the 1st quarter valued at $231,000. Finally, Xact Kapitalforvaltning AB acquired a new position in Mirati Therapeutics in the 1st quarter valued at $235,000.

About Mirati Therapeutics

Mirati Therapeutics, Inc, a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company is involved in developing sitravatinib, a spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of non-small cell lung cancer (NCSLC); and in Phase Ib clinical trial to treat NCSLC patients with Casitas B-lineage Lymphoma genetic alterations, as well as KRAS G12C inhibitor program for NSCLC adenocarcinoma patients, colorectal cancer patients, and other cancers.

See Also: Why are percentage decliners important?

Get a free copy of the Zacks research report on Mirati Therapeutics (MRTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Mirati Therapeutics (NASDAQ:MRTX)

Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.